Clinical Trial Results:
Phase Ib/II, Multicenter, Open-Label, Randomized, Clinical Study with Dose
Optimization of Two Different Schedules of Elisidepsin Trifluoroacetate
(Irvalec®) as a Single Agent in Patients with Unresectable, Locally Advanced or
Metastatic Esophageal, Esophagogastric Junction or Gastric Cancer After
Failure of One but not More than Two Prior Lines of Systemic Therapy
Summary
|
|
EudraCT number |
2010-020325-40 |
Trial protocol |
FR GB |
Global completion date |
04 May 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 Aug 2016
|
First version publication date |
05 Aug 2016
|
Other versions |
|
Summary report(s) |
2010-020325-40 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.